S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
NASDAQ:SPPI

Spectrum Pharmaceuticals - SPPI Stock Forecast, Price & News

$0.42
-0.02 (-4.52%)
(As of 12/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.42
▼
$0.45
50-Day Range
$0.38
▼
$0.52
52-Week Range
$0.36
▼
$1.62
Volume
924,045 shs
Average Volume
3.53 million shs
Market Capitalization
$79.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Spectrum Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
609.9% Upside
$3.00 Price Target
Short Interest
Healthy
4.40% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
0.85mentions of Spectrum Pharmaceuticals in the last 14 days
Based on 13 Articles This Week
Insider Trading
Acquiring Shares
$22,500 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.48) to ($0.25) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

170th out of 1,022 stocks

Pharmaceutical Preparations Industry

67th out of 499 stocks

See Top Rated MarketRank™ Stocks Here
SPPI stock logo

About Spectrum Pharmaceuticals (NASDAQ:SPPI) Stock

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.

Receive SPPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SPPI Stock News Headlines

December 9, 2022 | benzinga.com
National Law Firm Investigating Spectrum Pharmaceuticals, Inc. Over Alleged False/Misleading Statements Regarding New Drug Application
December 9, 2022 | benzinga.com
National Law Firm Investigating Spectrum Pharmaceuticals, Inc. Over Alleged False/Misleading Statements Regarding New Drug Application
December 9, 2022 | wsj.com
INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
December 8, 2022 | wsj.com
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
December 8, 2022 | americanbankingnews.com
Spectrum Pharmaceuticals (NASDAQ:SPPI) Coverage Initiated by Analysts at StockNews.com
December 7, 2022 | benzinga.com
CLASS ACTION UPDATE for SQ, ARGO and SPPI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
December 6, 2022 | benzinga.com
Bronstein, Gewirtz & Grossman, LLC Notifies Spectrum Pharmaceuticals, Inc. (SPPI) Investors of Class Action and to Actively Participate
December 6, 2022 | finance.yahoo.com
Spectrum Pharmaceuticals’ ROLVEDON™ (eflapegrastim-xnst) Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors
December 5, 2022 | finance.yahoo.com
Spectrum Pharmaceuticals Announces New Employment Inducement Grants for Commercial Staff
December 4, 2022 | americanbankingnews.com
Jeff L. Vacirca Purchases 50,000 Shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Stock
December 3, 2022 | wsj.com
Bragar Eagel & Squire, P.C. Is Investigating Spectrum, F45 Training, PROG, and Fox and Encourages Investors to Contact the Firm
November 29, 2022 | bizjournals.com
Boston cancer firm axes 75% of staff after FDA rejection
November 25, 2022 | marketwatch.com
Spectrum Pharmaceuticals Says Cancer Drug Failed to Win FDA Approval
November 25, 2022 | benzinga.com
Kaplan Fox Continues to Investigate Potential Securities Fraud at Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) - INVESTOR UPDATE
November 25, 2022 | markets.businessinsider.com
FDA Rejects Spectrum's Poziotinib, As Expected, Company To Cut R&D Workforce By 75%
November 25, 2022 | msn.com
U.S. FDA declines to approve Spectrum's lung cancer drug
November 25, 2022 | seekingalpha.com
Spectrum Pharma sheds 14% after FDA snub for lung cancer therapy
November 25, 2022 | markets.businessinsider.com
H.C. Wainwright Reaffirms Their Buy Rating on Spectrum Pharmaceuticals (SPPI)
November 21, 2022 | benzinga.com
Kaplan Fox Investigates Potential Securities Fraud at Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI)
November 16, 2022 | marketwatch.com
Spectrum Pharmaceuticals downgraded to neutral from buy at B. Riley
November 10, 2022 | seekingalpha.com
Spectrum Pharmaceuticals, Inc. (SPPI) Q3 2022 Earnings Call Transcript
November 4, 2022 | benzinga.com
Spectrum Pharmaceuticals, Inc. Shareholder Alert: Kaplan Fox Investigates Potential Securities Fraud
October 17, 2022 | finance.yahoo.com
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
October 3, 2022 | benzinga.com
Bragar Eagel & Squire, P.C. Is Investigating Cantaloupe, Compass, and Spectrum and Encourages Investors to Contact the Firm
September 23, 2022 | benzinga.com
Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) Investor Alert: Kaplan Fox Investigates Potential Securities Fraud
See More Headlines
Receive SPPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SPPI Company Calendar

Last Earnings
11/10/2022
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/16/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:SPPI
CUSIP
84763A10
CIK
831547
Web
www.sppirx.com
Phone
(702) 835-6300
Fax
702-260-7405
Employees
163
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+609.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.64)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-158,630,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-246.66%
Return on Assets
-103.55%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.28
Quick Ratio
2.09

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.29 per share
Price / Book
1.46

Miscellaneous

Outstanding Shares
188,164,000
Free Float
183,084,000
Market Cap
$79.52 million
Optionable
Optionable
Beta
2.02

Social Links


Key Executives

  • Mr. Thomas J. RigaMr. Thomas J. Riga (Age 47)
    Pres, CEO & Director
    Comp: $1.02M
  • Ms. Nora E. Brennan (Age 53)
    Exec. VP & Chief Financial Officer
    Comp: $54.17k
  • Mr. Keith M. McGahan J.D.Mr. Keith M. McGahan J.D. (Age 46)
    L.L.M., Exec. VP, Chief Legal Officer & Corp. Sec.
    Comp: $851.73k
  • Dr. Francois J. Lebel FRCPC (Age 70)
    M.D., Exec. VP & Chief Medical Officer
    Comp: $917.96k
  • Mr. Bimal R. Shah
    VP of Corp. & Bus. Devel.
  • Mr. Michael A. Grabow
    Exec. VP & Chief Bus. Officer
  • Dr. Lyndah K. Dreiling M.B.A.
    M.D., Sr. VP of Clinical Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













SPPI Stock - Frequently Asked Questions

Should I buy or sell Spectrum Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SPPI shares.
View SPPI analyst ratings or view top-rated stocks.

What is Spectrum Pharmaceuticals' stock price forecast for 2023?

4 analysts have issued 1 year target prices for Spectrum Pharmaceuticals' stock. Their SPPI share price forecasts range from $1.00 to $4.00. On average, they anticipate the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 586.5% from the stock's current price.
View analysts price targets for SPPI or view top-rated stocks among Wall Street analysts.

How have SPPI shares performed in 2022?

Spectrum Pharmaceuticals' stock was trading at $1.27 on January 1st, 2022. Since then, SPPI shares have decreased by 65.6% and is now trading at $0.4370.
View the best growth stocks for 2022 here.

When is Spectrum Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our SPPI earnings forecast.

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) released its quarterly earnings data on Thursday, November, 10th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.03.

What is Joseph Turgeon's approval rating as Spectrum Pharmaceuticals' CEO?

2 employees have rated Spectrum Pharmaceuticals Chief Executive Officer Joseph Turgeon on Glassdoor.com. Joseph Turgeon has an approval rating of 47% among the company's employees. This puts Joseph Turgeon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Spectrum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), OPKO Health (OPK), Bausch Health Companies (BHC), Sorrento Therapeutics (SRNE) and Zynerba Pharmaceuticals (ZYNE).

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

Who are Spectrum Pharmaceuticals' major shareholders?

Spectrum Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (8.86%), Vanguard Group Inc. (4.61%), BlackRock Inc. (3.84%), Renaissance Technologies LLC (0.53%), CM Management LLC (0.43%) and State Street Corp (0.33%). Insiders that own company stock include Francois Lebel, Jeff L Vacirca, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Nora Brennan, Seth H Z Fischer, Thomas J Riga and William Ashton.
View institutional ownership trends.

How do I buy shares of Spectrum Pharmaceuticals?

Shares of SPPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Spectrum Pharmaceuticals' stock price today?

One share of SPPI stock can currently be purchased for approximately $0.44.

How much money does Spectrum Pharmaceuticals make?

Spectrum Pharmaceuticals (NASDAQ:SPPI) has a market capitalization of $82.23 million. The biotechnology company earns $-158,630,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis.

How many employees does Spectrum Pharmaceuticals have?

The company employs 163 workers across the globe.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The official website for the company is www.sppirx.com. The biotechnology company can be reached via phone at (702) 835-6300, via email at ir@sppirx.com, or via fax at 702-260-7405.

This page (NASDAQ:SPPI) was last updated on 12/9/2022 by MarketBeat.com Staff